Thus, apoptosis-correlated factors are promising drug targets in BRAF-mutant cancers, but can also have limited activities in BRAF/MEK inhibitor-resistant cancers requiring further actions to eliminate resistant cells. This evidence concerns the gene MAP2K7 and cancer.